A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia
Latest Information Update: 06 Mar 2024
At a glance
- Drugs Celecoxib/famciclovir (Primary)
- Indications Fibromyalgia; Myofascial pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Innovative Med Concepts; Virios Therapeutics
- 01 Mar 2024 According to a Virios Therapeutics media release, the company is looking forward to go ahead towards phase 3 with potential partners to fund the advancement.
- 26 Jul 2021 According to a Virios Therapeutics media release, FORTRESS trial builds on the encouraging results from this study.
- 05 Jun 2021 Results of post-hoc analysis assessing effects of IMC-1 compared with placebo on other fibromyalgia symptoms, including lack of energy, stiffness, problems with sleep, problems with memory, depression, and anxiety, presented at the 22nd Annual Congress of the European League Against Rheumatism.